InterMune's entry, Actimmune, suppresses production of TGF-beta by disrupting the signals inside the factorylike fibroblast cells that make it.
FORBES: Scar Wars
2.
InterMune, however, is not betting everything on off-label use of Actimmune.
FORBES: InterMune Gets Around The FDA
3.
The results of that measurement were not significant, but researchers noticed something that might be more encouraging: Patients taking Actimmune were less like to die from IPF.